Compare AbbVie Inc (ABBV) vs New York Times Co (NYT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs New York Times Co — how do they compare? AbbVie Inc trades at $253.69 (market cap $449.91B), while New York Times Co trades at $73.95 (market cap $11.93B). The key difference: AbbVie Inc is far larger — about 37.7× New York Times Co's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | NYT | |
|---|---|---|
Market Cap | $449.91B | $11.93B |
Sector | Health | Media |
52-Week High | $261.07 | $85.86 |
52-Week Low | $184.85 | $51.43 |
Enterprise Value | $513.38B | $11.33B |
Dividend Yield | 2.72% | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
The New York Times Company (NYT) trades at $73.72, showing modest daily movement. The stock exhibits a bullish technical trend with strong moving average signals. Fundamentally, the company demonstrates consistent revenue growth, expanding profit margins, and robust cash flow from operations. Recent quarterly earnings have consistently surpassed analyst expectations, reflecting operational strength. A dividend of $0.23 per share is scheduled for payment in July 2026.
The outlook for NYT is positive, supported by solid financial performance and a 'Buy' analyst consensus with a $78.00 price target, implying potential upside. Key opportunities include sustained digital subscription growth and margin expansion. Primary risks involve competitive pressures in the media landscape and broader economic sensitivity affecting advertising revenue. The stock presents a compelling case for investors seeking a stable, growing media company.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
